| abstract |
Compounds, pharmaceutical compositions, and methods of treatment and prevention of diseases associated with NMDA receptor activity, including neuropathic pain, stroke, traumatic brain injury, epilepsy, and related neurological events or neurodegeneration are provided. . A compound of general formula I, or a pharmaceutically acceptable salt, ester, prodrug, or derivative thereof is provided. Wherein (L) k -Ar 1 is a substituted or unsubstituted monocyclic or bicyclic aryl or heteroaryl, W is a bond, alkyl, or alkenyl, X is a bond, NR 1 or O, each R 1 and R 2 is independently H, alkyl, alkenyl, or aralkyl, and R 1 and R 2 bonded together form a 5- to 8-membered ring; R 3 to R 6 are selected from certain specific substituents or carbonyl, and Y is a bond, O, S, SO, SO 2 , CH 2 , NH, N (alkyl), or NHC (═O). Yes, Z is OH, NR 6 R 7 , NR 8 SO 2 (alkyl), NR 8 C (O) NR 6 R 7 , NR 8 C (O) O (alkyl), NR 8 -dihydrothiazole, or NR 8 - dihydroimidazo Either a le, or Z is Ar 2 and fused, it is possible to form a selected heterocyclic ring.). |